Attention Deficit Hyperactivity Disorder (ADHD) News and Research

Latest Attention Deficit Hyperactivity Disorder (ADHD) News and Research

Comprehensive report details the prevalence, implications, costs of caregiving and demographics of caregivers

Caregiving is still mostly a woman's job and many women are putting their career and financial futures on hold as they juggle part-time caregiving and full-time job requirements.

9 Dec 2009

Increased sense of separation in this holiday season's most harmful gifts

A couple years ago, lead paint in toys manufactured in China sent parents searching frantically for gifts made in the USA. This fall, news of Baby Einstein refunds suggested that even so-called educational toys are suspect. Renowned parenting expert Dr. Jeffrey Fine, Ph.D., says that such videos are actually harmful to developing brains, retarding language development and shortening attention spans. Moreover, there is an increased sense of separation, which is the defining trait of each of this holiday season's most harmful gifts.

7 Dec 2009

Native Remedies selects TransMedia Group as its PR firm

With more than 500,000 customers worldwide, the market leader in all-natural herbal and homeopathic remedies for people and their pets, Native Remedies, has engaged TransMedia Group as their PR firm of record. The company's two brands, Native Remedies (www.nativeremedies.com) and PetAlive (www.PetAlive.com), provide complete lines of safe, scientifically-tested, guaranteed products that promote health and wellness - naturally.

7 Dec 2009

Overview of the important research and treatments in ADHD

Worldwide longitudinal studies performed since the 1970s have clearly shown that ADHD persists into adulthood. These findings have stimulated researchers to develop the therapeutic approaches for adult patients, especially in European countries where scientific and clinical interest in ADHD has increased.

4 Dec 2009

Analysis explores the importance of CNS-related conditions and their impact on epilepsy management

Depression, anxiety disorder, bipolar disorder, Attention Deficit Hyperactivity Disorder (ADHD), sleep disorder and migraine: These are among the comorbidities reported to occur more often in people who said they had been diagnosed with epilepsy versus those without an epilepsy diagnosis, according to a survey of approximately 173,000 households across the U.S.

4 Dec 2009

Shire voluntarily recalls specific lots of its Daytrana ADHD patches

Shire plc, the global specialty biopharmaceutical company, today announced a voluntary recall of five lots and voluntary market withdrawal of one lot of the Attention-Deficit/Hyperactivity Disorder (ADHD) patch Daytrana®. Shire is taking this action because some Daytrana patches do not meet or in the future may not meet their release liner removal specification, and as a result, patients and caregivers could have difficulty removing the liners.

3 Dec 2009

AstraZeneca and Targacept enter into agreement to develop and commercialize TC-5214

AstraZeneca and Targacept, Inc. today announced a collaboration and license agreement for the global development and commercialization of TC-5214, Targacept’s late-stage investigational product for major depressive disorder (MDD).

3 Dec 2009

MRI pioneer honored with MRC Millennium Medal

Sir Peter Mansfield, The University of Nottingham's Nobel Laureate for Physiology and Medicine, is to be recognised, once again, for his part in one of the most important breakthroughs in medical science.

2 Dec 2009

Findings show the relationship between neurotransmitter dopamine and ADHD

Scientists at the California Institute of Technology (Caltech) have uncovered evidence of a primitive emotion-like behavior in the fruit fly, Drosophila melanogaster.

26 Nov 2009

Children exposed to lead and tobacco are 2.4 times more likely to have ADHD

Children exposed prenatally to tobacco smoke and during childhood to lead face a particularly high risk for ADHD, according to research done at Cincinnati Children's Hospital Medical Center.

23 Nov 2009

New report finds positive association between phthalate exposure and ADHD symptoms

Phthalates are important components of many consumer products, including toys, cleaning materials, plastics, and personal care items. Studies to date on phthalates have been inconsistent, with some linking exposure to these chemicals to hormone disruptions, birth defects, asthma, and reproductive problems, while others have found no significant association between exposure and adverse effects.

19 Nov 2009

Shire publishes new study results on INTUNIV Extended-Release Tablets

Shire plc, the global specialty biopharmaceutical company, announced new study results on INTUNIV- (guanfacine) Extended-Release Tablets published in the October Journal of Child and Adolescent Psychopharmacology. In this open-label safety study, there was no evidence of unique adverse effects with the combination of INTUNIV and amphetamine or methylphenidate relative to what was observed with either medication alone.

17 Nov 2009

Addrenex Pharmaceuticals to be acquired by Sciele Pharma

Sciele Pharma, Inc., a U.S.-based group company of Shionogi & Co., Ltd. and Addrenex Pharmaceuticals, Inc., a privately-held U.S. pharmaceutical company specializing in developing drugs that regulate the adrenergic system, today announced that Sciele has agreed to acquire Addrenex.

16 Nov 2009

Findings from post hoc analysis examining emotional lability from Phase 3 study data with Vyvanse announced

Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announced findings from a post hoc analysis examining emotional lability from Phase 3 study data with Vyvanse-. In this study, Vyvanse demonstrated significant improvement in Attention-Deficit/Hyperactivity Disorder (ADHD) symptoms as measured by the ADHD Rating Scale IV (ADHD-RS IV) and Connors' Parent Rating Scale-Revised Short (CPRS-RS) in children with ADHD aged 6 to 12 years.

16 Nov 2009

Poor mental health in children and teenagers impacts on the length of time they will stay in school: Study

"Our study shows that poor mental health in children and teenagers has a large impact on the length of time they will stay in school," says Dr. Lehrer. He notes a large number of school-based programs have recently been introduced to prevent childhood obesity through lifestyle changes, but suggests the net should be cast more widely. "It's important for policymakers to target health conditions that are not the easiest to identify - like inattention - but may have larger impacts on one's future."

13 Nov 2009

Shire announces findings from Phase 3 study data with Vyvanse

Shire plc, the global specialty biopharmaceutical company, announced findings from a post hoc analysis examining emotional lability from Phase 3 study data with Vyvanse®. In this study, Vyvanse demonstrated significant improvement in Attention-Deficit/Hyperactivity Disorder (ADHD) symptoms as measured by the ADHD Rating Scale IV (ADHD-RS IV) and Connors' Parent Rating Scale-Revised Short (CPRS-RS) in children with ADHD aged 6 to 12 years.

13 Nov 2009

Malfunctioning circadian clock genes may be associated with bipolar disorder in children

Malfunctioning circadian clock genes may be responsible for bipolar disorder in children. Researchers writing in the open access journal BMC Psychiatry found four versions of the regulatory gene RORB that were associated with pediatric bipolar disorder.

11 Nov 2009

Online patient support program for ADHD patients taking Vyvanse Capsules CII medication

Shire plc (LSE: SHP, Nasdaq: SHPGY), the global specialty biopharmaceutical company, today announced the re-launch of FOCUS (http://www.vyvanseFOCUS.com), a free, online patient support program for adults taking once-daily Vyvanse® (lisdexamfetamine dimesylate) Capsules CII for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD), and the only online, branded personalized patient support program providing tips and tools for adults diagnosed with ADHD taking a prescription medication.

11 Nov 2009

Children and young people with autism should be offered special teaching support

Teachers and parents must be vigilant in observing difficulties with language comprehension, reading and spelling in children and young people with autism, Asperger's syndrome and ADHD.

10 Nov 2009

Shire's INTUNIV for treating ADHD now available in the U.S.

Shire plc, the global specialty biopharmaceutical company, today announced the availability of INTUNIV(TM) (guanfacine) Extended Release Tablets in pharmacies across the United States for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in children and adolescents ages 6 to 17.

9 Nov 2009

Attention Deficit Hyperactivity Disorder (ADHD) News and Research

Latest Attention Deficit Hyperactivity Disorder (ADHD) News and Research

Comprehensive report details the prevalence, implications, costs of caregiving and demographics of caregivers

Increased sense of separation in this holiday season's most harmful gifts

Native Remedies selects TransMedia Group as its PR firm

Overview of the important research and treatments in ADHD

Analysis explores the importance of CNS-related conditions and their impact on epilepsy management

Shire voluntarily recalls specific lots of its Daytrana ADHD patches

AstraZeneca and Targacept enter into agreement to develop and commercialize TC-5214

MRI pioneer honored with MRC Millennium Medal

Findings show the relationship between neurotransmitter dopamine and ADHD

Children exposed to lead and tobacco are 2.4 times more likely to have ADHD

New report finds positive association between phthalate exposure and ADHD symptoms

Shire publishes new study results on INTUNIV Extended-Release Tablets

Addrenex Pharmaceuticals to be acquired by Sciele Pharma

Findings from post hoc analysis examining emotional lability from Phase 3 study data with Vyvanse announced

Poor mental health in children and teenagers impacts on the length of time they will stay in school: Study

Shire announces findings from Phase 3 study data with Vyvanse

Malfunctioning circadian clock genes may be associated with bipolar disorder in children

Online patient support program for ADHD patients taking Vyvanse Capsules CII medication

Children and young people with autism should be offered special teaching support

Shire's INTUNIV for treating ADHD now available in the U.S.

Industry Focus eBook - Pharmaceutical manufacturing (2nd edition) eBook

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Attention Deficit Hyperactivity Disorder (ADHD) News and Research

Latest Attention Deficit Hyperactivity Disorder (ADHD) News and Research

Industry Focus eBook - Pharmaceutical manufacturing (2nd edition) eBook

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Newsletters you may be interested in